PointState Capital’s Bristol-Myers Squibb BMY Stock Holding History

PointState Capital’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-100,000	Closed	-$6.24M	–	79
2021 Q4	$6.24M	Buy	+100,000	New	+$5.87M	0.1%	79
2021 Q1	–	Sell	-50,000	Closed	-$3.1M	–	127
2020 Q4	$3.1M	Buy	+50,000	New	+$3.07M	0.06%	102
2019 Q2	–	Sell	-25,000	Closed	-$1.19M	–	116
2019 Q1	$1.19M	Buy	+25,000	New	+$1.25M	0.02%	110
2017 Q3	–	Sell	-830,000	Closed	-$46.2M	–	156
2017 Q2	$46.2M	Buy	830,000 +30,000	+4%	+$1.63M	0.5%	49
2017 Q1	$43.5M	Buy	+800,000	New	+$43.9M	0.45%	50

Other funds holding BMY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

PointState Capital's BMY Position: Q3 2022 in Review

PointState Capital sold out of Bristol-Myers Squibb (BMY) in Q3 2022, closing a stake of 47,235 shares — an estimated $3.64M sold.

PointState Capital first reported a position in BMY in Q4 2016 and held it in 8 quarters. The position peaked at $144M in Q1 2017. 2,470 funds tracked by Wall St. Rank hold BMY as of Q3 2022.

PointState Capital reported no remaining Bristol-Myers Squibb position as of Q3 2022 after selling out during the quarter.
PointState Capital sold 47,235 Bristol-Myers Squibb shares in Q3 2022, an estimated $3.64M.
PointState Capital first reported a position in Bristol-Myers Squibb in Q4 2016 and held it in 8 quarters.
PointState Capital's Bristol-Myers Squibb position peaked at $144M in Q1 2017.
2,470 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q3 2022.

Based on PointState Capital's 13F filing for Q3 2022, filed 10 Nov 2022.